江南·体育(JN SPORTS)官方网站,江南体育app下载

|
|
EN

  • 业务咨询

    中国：

    Email: marketing@hangzhouaijunshengwu.com

    业务咨询专线：400-780-8018

    （仅限服务咨询，其他事宜请拨打川沙总部电话）

    川沙总部电话: +86 (21) 5859-1500

    海外：

    +1(626)986-9880(U.S. - West Coast)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com
在线留言×
点击切换
Customer Center
客户中心

研究新型多靶点抗高血压药MT-1207的药理学特性，评价MT-1207的结合抑制活性通过美迪西进行

2023-07-05
|
访问量：

43.jpgHypertension is a serious public health problem worldwide. MT-1207 is a chemical entity that has entered into clinical trial as antihypertensive agent. MT-1207 potently inhibits adrenergic α1A, α1B, α1D, and 5-HT2A receptors with Ki<1 nM in a panel of enzyme activity or radioligand binding assays. The binding inhibition activities of MT-1207 were evalsuated by Medicilon. 

Reference:

Tian-Ying Xu, et al. Pharmacological characterization of MT-1207, a novel multitarget antihypertensive agent. Acta Pharmacol Sin. 2021 Jun;42(6):885-897. doi: 10.1038/s41401-021-00636-1. 


相关新闻
江南·体育(JN SPORTS)官方网站